|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 237.49 USD | -0.89% |
|
-4.46% | +14.69% |
| 05:01pm | Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment | MT |
| 04:46pm | Oil Shock Meets Job Shock |  |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | $235.25 | -1.83% | 24 | ||||||
| $1,214.34 | +23.5% | 29 | ||||||
| $248.86 | +7.11% | 29 | ||||||
| CHF 360.74 | +2.63% | 19 | ||||||
| GBX 218 | +10.94% | 21 | ||||||
| CHF 150.03 | -5.88% | 21 | ||||||
| $127.22 | +9.61% | 27 | ||||||
| $350.04 | -4.78% | 28 | ||||||
| $156.59 | +7.89% | 27 | ||||||
| DKK 330.95 | +33.1% | 21 | ||||||
| $28.43 | +6.82% | 26 | ||||||
| $62.16 | +2.34% | 25 | ||||||
| $535.56 | +16.22% | 27 | ||||||
| GBX 20.32 | -2.11% | 20 | ||||||
| €98.49 | +26.7% | 23 | ||||||
| ¥9,823.33 | +0.99% | 15 | ||||||
| ¥5,536.87 | -1.67% | 15 | ||||||
| CN¥82.39 | +53.36% | 17 | ||||||
| GBX 4.266 | +11.9% | 16 | ||||||
| €45.29 | +19.89% | 20 | ||||||
| Average | 981.46 | +10.84% | 22 | ||||||
| Weighted average by Cap. | 685.63 | +9.59% | 25 |
- Stock Market
- Equities
- JNJ Stock
- Sector Johnson & Johnson
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition